Article Text

Download PDFPDF

6ER-027 Improvement in self-management of biological DMARDS for patients with chronic inflammatory arthritis when a pharmacist participates in a multidisciplinary consultation
  1. C Bottois1,
  2. J Hubert1,
  3. C Lopez-Medina2,
  4. S Dumas1,
  5. S Belo1,
  6. C Roux2,
  7. M Dougados2,
  8. O Conort1
  1. 1Hôpital Cochin, Clinical Pharmacy, Paris, France
  2. 2Hôpital Cochin, Rheumatology, Paris, France


Background and importance Enhancement of information for patients with chronic inflammatory arthritis (IA) on the management of subcutaneous (SC) biological DMARDs (bDMARDs) by the intervention of several successive health professionals should improve their necessary safety knowledge and skills for optimised self-management of their treatments.

Aim and objectives To assess the pharmacist’s contribution to improving knowledge and skills of patients with IA treated with SC bDMARDs during multidisciplinary consultations (MC). The secondary objectives were to assess the impact on therapeutic adherence and patient satisfaction.

Material and methods This was a prospective, single centre, 6 month trial, approved by the ethics committee. Inclusion criteria were patient with IA receiving SC bDMARDs. The intervention was an interview aimed at enhancing the patient’s knowledge and adherence. At baseline (M0), 3 months (M3) and 6 months (M6), knowledge and adherence were assessed using self-administered questionnaires, respectively, Biosecure and CQR-5. A patient satisfaction questionnaire was sent at M3. The main outcome was comparison of the Biosecure score at baseline, M3 and M6. Secondary outcomes were comparison of the rate of patients with a high level of knowledge and high adherence at baseline, M3 and M6, and patient satisfaction. For statistical analysis, different tests were used: repeated measures ANOVA, Bonferroni and generalised estimating equation.

Results The study was conducted from October 2019 to July 2020. 79 patients were included (aged 50.4±14.7 years; sex ratio 1.1). At M0, M3 and M6, Biosecure scores were 70.9±18.1, 81.7±15 and 84.3±13.7, respectively. A significant difference between scores was found as well as between each time point (p<0.001). At M0, M3 and M6, the rate of patients with a high level of knowledge was 24.1%, 54.4% and 45.6%, respectively, with a significant difference (p<0.001). No difference was observed concerning the rate of patients with high adherence (p=0.077). Patient satisfaction regarding the pharmaceutical interview was 24.9±3.1 (max=28).

Conclusion and relevance Participation of the pharmacist in the MC allowed for a significant improvement in patient knowledge of their bDMARDs. Regarding adherence, no significant difference can be explained by the already high level. This study highlights the positive impact of MC on patient knowledge of their SC bDMARDs, as well as patient satisfaction.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.